BOSTON, Sept. 18,
2024 /PRNewswire/ -- Today, Ginkgo Bioworks
(NYSE: DNA), which is building the leading platform
for cell programming and biosecurity, proudly announces the launch
of Ginkgo Datapoints to usher in the next era of biotechnology by
making the training of AI models easier and more efficient.
Ginkgo Datapoints is specialized in generating large, high-quality
biological datasets with a fast turnaround time and at a
competitive price per datapoint with a streamlined deal structure.
Ginkgo Datapoints will launch with several data generation products
this Fall including protein characterization and functional
genomics.
The Functional Genomics product, the flagship offering under
Ginkgo Datapoints, available now, delivers large-scale perturbation
datasets that power our partners' AI models of cell and disease
biology for use in target identification and validation and drug
discovery. Ginkgo Datapoints addresses some of the most significant
challenges in the industry for AI model training: data
availability, quality, and uniformity.
Jason Kelly, CEO of Ginkgo
Bioworks: "The launch of Ginkgo Datapoints marks a significant
step forward in our mission to make biology easier to engineer.
With Ginkgo Datapoints, we're passing on our economies of scale to
our customers by generating large, high-quality datasets for our
customers at a price per dataset that makes training biological
foundation models feasible. Ginkgo Datapoints is more than just a
service—it's a commitment to driving innovation and accelerating
the development of new therapies and solutions across the biotech
industry."
John Androsavich, General
Manager of Ginkgo Datapoints: "There's a burgeoning market of
drug and product developers who want to take advantage of AI, and
their models are ravenous for data. With Ginkgo Datapoints, we're
answering the call for how to generate the data this new era of
life sciences needs. We're focusing Ginkgo's massive infrastructure
to do biological data generation at AI scale, allowing our
Datapoints customers to make bold bets in model training that will
meaningfully impact drug discovery for target ID or fields like
antibody therapeutics. Our goal is to eliminate the data
bottlenecks slowing down AI-driven advancements in biology, and I'm
excited about the team and technologies we've assembled for
it."
Ginkgo Datapoints products are the next evolution of Ginkgo's
previously launched Lab Data-as-a-Service offerings. These products
will offer key features that are of critical importance to
customers building AI for biology, ranging from biopharmas to
techbio to big tech companies. Ginkgo Datapoints' Functional
Genomics product is designed for:
- Flexibility and Customizability: Customers provide their
sequences or library inputs and choose the dataset design that's
right for them, selecting from a number of ready-to-go product
parameters. Variables include dataset size, cell lines or primary
cells of choice, assay readouts, and data format and labeling
preferences. Customers can also consult with Ginkgo's AI experts to
receive design recommendations for their application, customized to
whether the datasets will be used to train foundation models or
task-specific models, to validate existing models, or pursue
another outcome such as hit discovery.
- Scalability and Speed: Leveraging Ginkgo's
state-of-the-art automation and backend data management
infrastructure, Ginkgo Datapoints can routinely deliver millions of
data points by screening customer libraries to generate rich, high
quality, neatly-compiled high throughput transcriptome, cell
painting, or other omics profiling data in as little as three
weeks.
- Data Quality and Cost Efficiency: Due to the scale
economies of Ginkgo's highly automated lab, Ginkgo Datapoints can
offer volume discounts as datasets grow in size, making it feasible
to feed data-hungry AI models.
- Attractive Deal Terms: Customers own the data generated
by Ginkgo Datapoints, acquiring it through fee-for-service
pricing.
Ginkgo Datapoints embodies Ginkgo's mission of making biology
easier to engineer by unlocking the full potential of AI in
biology. By generating the data that the industry needs, Ginkgo
Datapoints is poised to be a vital resource for researchers and
companies leveraging AI and machine learning for drug discovery and
beyond.
Unlock AI. Unlock Biology. Learn more about Ginkgo
Datapoints and how we can accelerate your AI efforts with our
cutting-edge data services here.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell
programming, providing flexible, end-to-end services that solve
challenges for organizations across diverse markets, from food and
agriculture to pharmaceuticals to industrial and specialty
chemicals. Ginkgo Biosecurity is building and deploying the
next-generation infrastructure and technologies that global leaders
need to predict, detect, and respond to a wide variety of
biological threats. For more information, visit ginkgobioworks.com
and ginkgobiosecurity.com, read our blog, or follow us on social
media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram
(@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
GINKGO BIOWORKS INVESTOR
CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA
CONTACT:
press@ginkgobioworks.com
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the capabilities and potential success of
Ginkgo Datapoints and Ginkgo's cell programming platform. These
forward-looking statements generally are identified by the words
"believe," "can," "project," "potential," "expect," "anticipate,"
"estimate," "intend," "strategy," "future," "opportunity," "plan,"
"may," "should," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) volatility in the price of Ginkgo's securities due
to a variety of factors, including changes in the competitive and
highly regulated industries in which Ginkgo operates and plans to
operate, variations in performance across competitors, and changes
in laws and regulations affecting Ginkgo's business, (ii) the
ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional business
opportunities, (iii) the risk of downturns in demand for products
using synthetic biology, (iv) the uncertainty regarding the demand
for passive monitoring programs and biosecurity services, (v)
changes to the biosecurity industry, including due to advancements
in technology, emerging competition and evolution in industry
demands, standards and regulations, (vi) the outcome of any pending
or potential legal proceedings against Ginkgo, (vii) our ability to
realize the expected benefits from and the success of our Foundry
platform programs, (viii) our ability to successfully develop
engineered cells, bioprocesses, data packages or other
deliverables, and (ix) the product development or commercialization
success of our customers. The foregoing list of factors is not
exhaustive. You should carefully consider the foregoing factors and
the other risks and uncertainties described in the "Risk Factors"
section of Ginkgo's annual report on Form 10-K filed with the U.S.
Securities and Exchange Commission (the "SEC") on February 29, 2024, Ginkgo's most recent quarterly
report on Form 10-Q, and other documents filed by Ginkgo from time
to time with the SEC. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Ginkgo assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Ginkgo does not give any assurance
that it will achieve its expectations.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-launches-ginkgo-datapoints-to-transform-ai-model-training-in-biology-302251751.html
SOURCE Ginkgo Bioworks